Neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal complication
of antipsychotic medication. The risk of developing NMS under atypical neuroleptics
seems lower than under typical neuroleptics. However, the use of atypical neuroleptics
in modern psychopharmacotherapy is increasing, so the incidence of NMS under these
drugs may also increase. Here, we will describe three episodes of NMS that fulfilled
the DSM-IV criteria for NMS (APA, 1994). The epivodes of NMS occured under treatment
with clozapine, risperidone, and amisulpride. These episodes had some atypical features
that will be discussed with regard to the pathophysiological mechanisms leading to
NMS.
References
- 1
Addonizio G, Susman V L, Roth S D.
Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients.
Am J Psychiatry.
1986;
143
1587-1590
- 2 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. Fourth
Edition. Washington D.C. 1994
- 3
Anderson E S, Powers P S.
Neuroleptic malignant Syndrome Associated With Clozapine Use.
J Clin Psychiatry.
1991;
52
102-104
- 4
Bajjoka I, Patel T, O'Sullivan T.
Risperidone-induced neuroleptic malignant syndrome.
Ann Emerg Med,.
1997;
30
698-700
- 5
Blumer D.
Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings.
Compr Psychiatry.
1997;
38
(4)
193-201
- 6
Corrigan F M, Coulter F.
Neuroleptic malignant syndrome, amitriptyline and thioridazine.
Biol Psychiatry.
1988;
23
320-321
- 7
DasGupta K, Young A.
Clozapine-Induced Neuroleptic Malignant Syndrome.
J Clin Psychiatry.
1991;
52
105-107
- 8
Eikmeier G, Muszynski K, Berger M, Gastpar M.
High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial.
Pharmacopsychiatry.
1990;
23
(5)
212-214
- 9
Fink M.
Toxic Serotonin Syndrome or Neuroleptic Malignant Syndrome.
Pharmacopsychiat.
1996;
29
159-161
- 10
Gurrera R J.
Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome.
Am J Psychiatry.
1999;
156
169-180
- 11
Hegerl U, Bottlender R, Gallinat J. et al .
The serotonin syndrome scale: first results on validity.
Eur Arch Psychiatry Clin Neurosci.
1998;
248
96-103
- 12
Iwahashi K.
CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome.
Biol Psychiatry.
1994;
36
781-782
- 13
Karagianis J L, Phillips L C, Hogan K P. et al .
Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of
the literature.
Ann-Pharmacother.
1999;
33
623-630
- 14
Kawanishi C, Shimoda Y, Fujimaki J, Onishi H, Suzuki K, Hanihara T, Sugiyama N, Kosaka K.
Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant
syndrome.
J Neurol Sci.
1998;
160
(1)
102-104
- 15
Kern J L, Cernek P K.
Delayed risperidone-induced neuroleptic malignant syndrome.
Ann Pharmacother.
1996;
30
(3)
300
- 16
Lee M S, Lee H J, Kim L.
A case of delayed NMS induced by risperidone.
Psychiatr Serv.
2000;
51
(2)
254-255
- 17
Merriam A E.
Withdrawal NMS after drug treatment.
Biol Psychiatry.
1988;
24
(3)
368-369
- 18
Miller D D, Sharafuddin J A, Kathol R G.
A Case of Clozapine-Induced Neuroleptic Malignant Syndrome.
J Clin Psychiatry.
1991;
52
99-101
- 19
Miyaoka H, Kamijima K.
Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and
serotonin syndrome spectrum disorders?.
Int Clin Psychopharmacol.
1995;
10
265-267
- 20
Newman M, Adityanjee , Jampala C.
Atypical neuroleptic malignant syndrome associated with risperidon treatment (letter).
Am J Psychiatry.
1997;
154
1475
- 21
Pope H G, Keck P E , McElroy S L.
Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric
hospital.
Am J Psychiatry.
1986;
143
1227-1233
- 22
Ram A, Cao Q, Keck P E, Pope H G, Otani K, Addonizio G, McElroy S L, Kaneko S, Redlichova M,
Gershon E S, Gejman P V.
Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant
syndrome.
Am J Med Genet.
1995;
60
228-230
- 23
Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A.
Myotoxicity and neurotoxicity during clozapine treatment.
Clin Neuropharmacol.
2000;
23
276-280
- 24
Shaley A, Munitz H.
The Neuroleptic Malignant Syndrome. Agent and host interaction.
Acta Psychiatr.
Scand1986;
73
337
- 25
Sharma R, Trappler B, Ng Y K, Leeman C P.
Risperidone-induced neuroleptic malignant syndrome.
Ann Pharmakother.
1996;
30
775-778
- 26
Singer S, Richards C, Boland R J.
Two cases of risperidone-induced neuroleptic malignant syndrome (letter).
Am J Psychiatry.
1995;
152
1234
- 27
Spivak B, Weizman A, Wolovick L. et al .
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
Acta Psychiatr Scand.
1990;
81
168-169
- 28
Stanilla J K, de Leon J, Simpson G M.
Clozapine withdrawal resulting in delirium with psychosis: a report of three cases.
J Clin Psychiatry.
1997;
58
252-255
- 29
Sternbach H.
The serotonin syndrome.
Am J Psychiatry.
1991;
148
705-713
Ronald Bottlender, MD
Psychiatrische Klinik der Ludwig-Maximilians-Universität
Nussbaumstr. 7
80336 München
Germany
Phone: +49-89-5160-5751
Fax: +49-89-5160-4749
Email: bottlend@psy.med.uni-muenchen.de
